MRNS Marinus Pharmaceuticals Inc.

3.62
-0.09  -2%
Previous Close 3.71
Open 3.6
Price To Book 4.16
Market Cap 146700547
Shares 40,525,013
Volume 1,999,320
Short Ratio
Av. Daily Volume 1,260,817

SEC filingsSee all SEC filings

  1. 8-K - Current report 181236280
  2. 424B5 - Prospectus [Rule 424(b)(5)] 181233946
  3. 424B5 - Prospectus [Rule 424(b)(5)] 181229171
  4. 8-K - Current report 181224871
  5. 8-K - Current report 181223498

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due 4Q 2018.
Ganaxolone
Refractory status epilepticus (RSE)
Data due 1H 2019.
Ganaxolone - Magnolia
Postpartum depression
Phase 2 data released June 2016. Primary endpoint not met but intends to advance development
Ganaxolone
Fragile X Syndrome
Phase 3 data did not meet endpoints - June 2016
Ganaxolone
Focal onset seizures
Phase 3 trial initiation announced June 19, 2018.
Ganaxolone
CDKL5 disorder
Phase 2 data due 1H 2019
Ganaxolone - oral (Amaryllis)
Postpartum depression

Latest News

  1. Marinus Pharmaceuticals plans $45M stock sale
  2. Marinus Pharmaceuticals Announces Pricing of Public Offering of Common Stock
  3. Here's Why Marinus Pharmaceuticals Is Sinking Today
  4. The Daily Biotech Pulse: Legal Victory For Boston Scientific, Alder Gets New CFO, FDA Go-Ahead For BioXcel
  5. Marinus Pharmaceuticals Announces Public Offering of Common Stock
  6. Marinus Pharma's Postpartum Depression Candidate Aces Midstage Trials
  7. Marinus Pharmaceuticals Announces Positive Ganaxolone Data in Women With Postpartum Depression
  8. Marinus Pharmaceuticals Phase 2 Clinical Trial Data Show Long-term Effectiveness of Ganaxolone in Reducing Seizure Frequency in CDKL5 Deficiency Disorder Patients
  9. Marinus Pharmaceuticals to Present Ganaxolone Clinical Trial Data in CDKL5 Deficiency Disorder and PCDH19-Related Epilepsy at AES
  10. Granite Point Capital’s Returns, AUM, and Holdings
  11. Is the Options Market Predicting a Spike in Marinus Pharmaceuticals (MRNS) Stock?
  12. Research Report Identifies Oil States International, Brightcove, Electronics for Imaging, Cirrus Logic, Innoviva, and Marinus Pharmaceuticals with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
  13. Marinus Pharmaceuticals: 3Q Earnings Snapshot
  14. Marinus Pharmaceuticals Provides Business Update and Third Quarter 2018 Financial Results
  15. Marinus Pharmaceuticals Names Dr. Rolando Gutíerrez-Esteinou as VP of Clinical Development and Pharmacovigilance
  16. Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)
  17. Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  18. What Kind Of Shareholders Own Marinus Pharmaceuticals Inc (NASDAQ:MRNS)?
  19. Marinus Completes Enrollment in its Magnolia Postpartum Depression Study

SEC Filings

  1. 8-K - Current report 181236280
  2. 424B5 - Prospectus [Rule 424(b)(5)] 181233946
  3. 424B5 - Prospectus [Rule 424(b)(5)] 181229171
  4. 8-K - Current report 181224871
  5. 8-K - Current report 181223498
  6. 8-K - Current report 181216859
  7. 8-K - Current report 181146943
  8. 10-Q - Quarterly report [Sections 13 or 15(d)] 181144250
  9. 8-K - Current report 181055163
  10. 10-Q - Quarterly report [Sections 13 or 15(d)] 18989804